NCT04619316 (ERRITI) is a Phase 2 clinical trial of Trametinib 2 MG [Mekinist] in Metastatic Thyroid Cancer, sponsored by University Hospital, Essen.

Who is sponsoring NCT04619316?

NCT04619316 is sponsored by University Hospital, Essen.

What drugs are being tested in NCT04619316?

Interventions in NCT04619316: Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar].

What condition does NCT04619316 study?

NCT04619316 studies Metastatic Thyroid Cancer.

Is NCT04619316 still recruiting?

NCT04619316 is currently status unknown. Last updated 22 June 2023.

Last reviewed 2023-06-22 · How we verify

NCT04619316: ERRITI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

Status unknown Phase 2 Last updated 22 June 2023

What this trial tests

Phase 2 trial testing Trametinib 2 MG [Mekinist] in Metastatic Thyroid Cancer in 70 participants. Status unknown.

Timeline

5 February 2018

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	University Hospital, Essen
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	5 February 2018
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Germany

Drugs / interventions tested

Trametinib 2 MG [Mekinist] — full drug profile →
Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar] — full drug profile →

Conditions studied

Metastatic Thyroid Cancer — all drugs for Metastatic Thyroid Cancer →

Sponsor

University Hospital, Essen

Who can join

18 and older, any sex, with Metastatic Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
Weber M, Kersting D, Riemann B, Brandenburg T, et al · · 2022 · cited 49× · PMID 35594174 · DOI 10.1158/1078-0432.ccr-22-0437
Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
Ratajczak M, Gaweł D, Godlewska M. · · 2021 · cited 37× · PMID 34769260 · DOI 10.3390/ijms222111829
Molecular features of aggressive thyroid cancer.
Elia G, Patrizio A, Ragusa F, Paparo SR, et al · · 2022 · cited 26× · PMID 36605433 · DOI 10.3389/fonc.2022.1099280
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement.
Leboulleux S, Boucai L, Busaidy N, Durante C, et al · · 2025 · cited 10× · PMID 40318680 · DOI 10.1016/s2213-8587(25)00064-6
Systemic treatments for radioiodine-refractory thyroid cancers.
Chen P, Yao Y, Tan H, Li J. · · 2024 · cited 9× · PMID 39473507 · DOI 10.3389/fendo.2024.1346476
Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Cortas C, Charalambous H. · · 2023 · cited 7× · PMID 38255638 · DOI 10.3390/life14010022
Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights.
Hiromasa T, Wakabayashi H, Watanabe S, Yamase T, et al · · 2025 · cited 3× · PMID 40067410 · DOI 10.1530/etj-24-0319
Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA. · · 2022 · cited 3× · PMID 36202606 · DOI 10.1002/cam4.5105

Verify or expand the search:

Other recruiting trials for Metastatic Thyroid Cancer

Currently open trials in the same condition.

NCT05668962 — Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC · Phase 2 · recruiting

Other University Hospital, Essen trials

Trials by the same sponsor.

NCT07409584 — Mental Health and Suicidality in Glioblastoma Patients in Germany · recruiting
NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
NCT06388369 — Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer · Phase 1, PHASE2 · terminated
NCT07130526 — Distrupt Stiffness Trial · NA · recruiting
NCT07343466 — Quality of Life and the Influence of Stress on the Postoperative Course of Patients After Device Implantation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04619316 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Essen
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04619316.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing